Protara Therapeutics, Inc. (TARA)
NASDAQ: TARA · Real-Time Price · USD
5.18
-0.04 (-0.77%)
Apr 9, 2026, 10:51 AM EDT - Market open
Protara Therapeutics Employees
Protara Therapeutics had 46 employees as of December 31, 2025. The number of employees increased by 18 or 64.29% compared to the previous year.
Employees
46
Change (1Y)
18
Growth (1Y)
64.29%
Revenue / Employee
n/a
Profits / Employee
-$1,248,674
Market Cap
280.16M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 46 | 18 | 64.29% | 46 | 0 |
| Dec 31, 2024 | 28 | 1 | 3.70% | 28 | 0 |
| Dec 31, 2023 | 27 | 2 | 8.00% | 26 | 1 |
| Dec 31, 2022 | 25 | -6 | -19.35% | 25 | 0 |
| Dec 31, 2021 | 31 | 4 | 14.81% | 31 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Abeona Therapeutics | 226 |
| LENZ Therapeutics | 152 |
| Foghorn Therapeutics | 106 |
| C4 Therapeutics | 104 |
| Silence Therapeutics | 88 |
| Editas Medicine | 87 |
| Surrozen | 44 |
| Inhibikase Therapeutics | 35 |
TARA News
- 4 weeks ago - Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update - GlobeNewsWire
- 6 weeks ago - TARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer - GlobeNewsWire
- 7 weeks ago - Protara Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Protara Therapeutics to Present Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Unresponsive NMIBC Patients at the ASCO Genitourinary Cancers Symposium - GlobeNewsWire
- 3 months ago - Protara Therapeutics Highlights Recent Updates and Anticipated 2026 Milestones - GlobeNewsWire
- 3 months ago - Protara Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 3 months ago - Protara Therapeutics Receives Both FDA Breakthrough Therapy and Fast Track Designations for TARA-002 in Pediatric Patients with Lymphatic Malformations - GlobeNewsWire